US pharma giant Merck & Co said its TROP2-directed antibody-drug conjugate sacituzumab tirumotecan (sac-TMT) reduced the risk ...

US pharma major AbbVie today announced the submission of a Biologics License Application (BLA) to the US Food and Drug ...

Danish biotech Ascendis Pharma has announced new data demonstrating early, sustained, and clinically meaningful improvements ...

Swiss pharma giant Novartis’ shares edged up 2% to 130.00 in early trading as the company reported third quarter 2026 ...

US biotechnology EIT Pharma, which focused on advancing therapies for infectious diseases, today appointed Dr Jose Toerne as ...

US pharma major Johnson & Johnson has reported Phase I results for JNJ-6143 (formerly HLD-0915), an investigational ...

US clinical-stage biopharma Corxel Pharmaceuticals, which is focused on developing innovative oral therapies for obesity and ...

The US Food and Drug Administration (FDA) has expanded approval of Pfizer’s Talzenna (talazoparib) in combination with Xtandi (enzalutamide ...

The diagnosed prevalent cases of ulcerative colitis (UC) in the seven major markets (7MM: The USA, France, Germany, Italy, ...

UK-based GSK and its licensor Hansoh Pharma said the pivotal Phase III ARTEMIS-011 trial of risvutatug rezetecan (Ris-Rez), ...

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) as a ...

Chiesi Global Rare Diseases, the rare diseases business unit of Italy’s family-run Chiesi Group, announced three poster ...